866-997-4948(US-Canada Toll Free)

PharmaPoint: Obesity - UK Drug Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Oct 2013

Category :

Metabolic Disorders

No. of Pages : 112 Pages

PharmaPoint: Obesity - UK Drug Forecast and Market Analysis to 2022

Summary

After a more than decade long dormancy, the Obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade.

Although the prevalence of obesity in the UK is one of the highest among the EU countries, it is a severely underserved market, with Xenical and its generic being the sole therapies for chronic weight management. Due to the high cost of therapy, most patients have been taking generic orlistat. In the UK, overweight and obesity are traditionally treated with lifestyle modifications, such as dietary regulation and increased physical activity.

Scope

- Overview of Obesity including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the UK from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the UK Obesity market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Obesity.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of drug performance.
- Obtain sales forecast for drugs from 2012-2022 in the UK.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 11
2.2 Related Reports 12
3 Disease Overview 14
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 17
3.1.3 Prognosis 17
3.1.4 Quality of Life 18
3.2 Symptoms 18
4 Disease Management 19
4.1 Treatment Overview 19
4.2 UK 24
4.2.1 Diagnosis 24
4.2.2 Clinical Practice 25
5 Competitive Assessment 27
5.1 Overview 27
5.2 Strategic Competitor Assessment 31
5.3 Product Profiles: Drugs 33
5.3.1 Xenical (orlistat) 33
5.3.2 Belviq (lorcaserin) 36
5.3.3 Oblean (cetilistat) 41
6 Opportunity and Unmet Need 44
6.1 Overview 44
6.2 A Drug with Greater Than 10% Average Weight Loss 45
6.2.1 Unmet Need 45
6.2.2 Gap Analysis 46
6.2.3 Opportunity 47
6.3 A Drug with Increased Safety and Tolerability 47
6.3.1 Unmet Need 47
6.3.2 Gap Analysis 48
6.3.3 Opportunity 48
6.4 Reimbursement by Private and Public Payers 48
6.4.1 Unmet Need 48
6.4.2 Gap Analysis 50
6.4.3 Opportunity 50
6.5 Increased Physician Education 50
6.5.1 Unmet Need 50
6.5.2 Gap Analysis 51
6.5.3 Opportunity 51
6.6 Increased Drug-Treatment Rate 52
6.6.1 Unmet Need 52
6.6.2 Gap Analysis 52
6.6.3 Opportunity 53
6.7 Improved Guidelines 53
6.7.1 Unmet Need 53
6.7.2 Gap Analysis 54
6.7.3 Opportunity 54
6.8 Improved Approach to Diagnosis 54
6.8.1 Unmet Need 54
6.8.2 Gap Analysis 55
6.8.3 Opportunity 55
7 Pipeline Assessment 56
7.1 Overview 56
7.2 Promising Drugs in Clinical Development 59
7.2.1 Contrave 62
7.2.2 Victoza (liraglutide) 67
7.2.3 Velneperit 72
7.2.4 Empatic 76
8 Market Outlook 81
8.1 United Kingdom 82
8.1.1 Forecast 82
8.1.2 Key Events 86
8.1.3 Drivers and Barriers 87
9 Appendix 90
9.1 Bibliography 90
9.2 Abbreviations 96
9.3 Research Methodology 98
9.4 Forecasting Methodology 98
9.4.1 Percent Drug-Treated Obesity Patients 99
9.4.2 Drugs Included in Each Therapeutic Class 99
9.4.3 Launch and Patent Expiry Dates 100
9.4.4 General Pricing Assumptions 100
9.4.5 Individual Drug Assumptions 101
9.4.6 Generic Erosion 104
9.4.7 Pricing of Pipeline Agents 104
9.5 Physicians, Specialists, and Payers Included in This Study 105
9.6 About the Authors 108
9.6.1 Analysts 108
9.6.2 Therapy Director - CVMD and Infectious Disease 109
9.6.3 Director - Medical Devices 109
9.6.4 Global Head of Healthcare 110
9.7 About GlobalData 111
9.8 Disclaimer 111

List of Table

1.1 List of Tables
Table 1: Target Pathways in the Treatment of Obesity 17
Table 2: Symptoms of Obesity 18
Table 3: Treatment Guidelines for Obesity 22
Table 4: Most Prescribed Drugs for Obesity by Class in the Global Markets, 2013 23
Table 5: Classification of Overweight and Obesity by BMI and Waist Circumference, and the Associated Disease Risk 24
Table 6: Bariatric Treatment Attributes 30
Table 7: Leading Drug Treatments for Obesity, 2013 31
Table 8: Marketed Obesity Treatment Devices by Type 32
Table 9: Product Profile - Xenical 34
Table 10: Xenical SWOT Analysis, 2013 36
Table 11: Product Profile - Belviq 38
Table 12: Belviq SWOT Analysis, 2013 40
Table 13: Product Profile - Oblean 42
Table 14: ObleanSWOT Analysis, 2013 43
Table 15: Unmet Need and Opportunity in Obesity 45
Table 16: Endpoint Analysis of Clinical Trials Conducted in Obesity, 2013 58
Table 17: Obesity - Phase II-III Pipeline, 2013 59
Table 18: Comparison of Therapeutic Classes in Development for Obesity, 2013 61
Table 19: Obesity Treatment Pipeline Devices by Type 61
Table 20: Product Profile - Contrave 63
Table 21: Contrave SWOT Analysis, 2013 66
Table 22: Product Profile - Victoza 68
Table 23: Victoza SWOT Analysis, 2013 72
Table 24: Product Profile - Velneperit 73
Table 25: Velneperit SWOT Analysis, 2013 76
Table 26: Product Profile - Empatic 77
Table 27: Empatic SWOT Analysis, 2013 80
Table 28: Sales Forecasts ($) for Obesity in United Kingdom, 2012-2022 84
Table 29: Key Events Impacting Sales for Obesity in the United Kingdom, 2012-2022 86
Table 30: Obesity Market in the United Kingdom - Drivers and Barriers, 2012-2022 87
Table 31: Key Launch Dates 100
Table 32: Key Patent Expiries 100

List of Chart

1.2 List of Figures
Figure 1: Treatment Algorithm for Obesity 21
Figure 2: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in the United Kingdom, 2012-2022 25
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Obesity, 2012-2022 60
Figure 4: Sales for Obesity in the United Kingdom by Drug Class, 2012-2022 85

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *